Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe

CRANBURY, N.J., Feb 27, 2009—Amicus Therapeutics announced today that the Company has suspended enrollment for the Phase 2 clinical trial of its investigational drug AT2220 (1-deoxynojirimycin HCI) for the treatment of Pompe Disease and that it has received verbal notice from the U.S. Food and Drug Administration (FDA) that the trial is on clinical hold. After evaluation of available data the Company plans to work closely with the FDA and if appropriate will amend the Phase 2 protocol with the objective of restarting the trial as expeditiously as possible.